Show simple item record

dc.contributor.authorCastelblanco Echavarría, Esmeralda
dc.contributor.authorSanjurjo, Lucía
dc.contributor.authorFalguera, Mireia
dc.contributor.authorHernández García, Marta
dc.contributor.authorFernandez-Real, Jose Manuel
dc.contributor.authorSarrias, Maria-Rosa
dc.contributor.authorAlonso, Núria
dc.contributor.authorMauricio Puente, Dídac
dc.date.accessioned2019-12-20T11:40:54Z
dc.date.available2019-12-20T11:40:54Z
dc.date.issued2019-05
dc.identifier.issn2077-0383
dc.identifier.urihttp://hdl.handle.net/10459.1/67766
dc.description.abstractThe aim of this study was to determine whether plasma concentrations of sCD36 (soluble CD36) are associated with the presence of type 1 or type 2 diabetes. Plasma levels of sCD36 were analysed in 1023 subjects (225 type 1 diabetes (T1D) patients, 276 type 2 diabetes (T2D) patients, and 522non-diabeticcontrolsubjects)usinganenzyme-linkedimmunosorbentassay(ELISA).Multinomial andlogisticregressionmodelswereperformedtoevaluateassociationswithsCD36anditsassociation with diabetes types. There were no significant differences in sCD36 (p = 0.144) among study groups, neither in head-to-head comparisons: non-diabetic versus T1D subjects (p = 0.180), non-diabetic versus T2D subjects (p = 0.583), and T1D versus T2D patients (p = 0.151). In the multinomial model, lower sCD36 concentrations were associated with older age (p < 0.001), tobacco exposure (p = 0.006), T2D (p = 0.020), and a higher-platelets count (p = 0.004). However, in logistic regression models of diabetes, sCD36 showed only a weak association with T2D. The current findings show a weak association of circulating sCD36 with type 2 diabetes and no association with T1D.ca_ES
dc.description.sponsorshipThis research was supported by grants from the European Foundation for the Study of Diabetes (2014-EFSD-00914). CIBERfor Diabetes andAssociated MetabolicDiseases (CIBERDEM) andCIBER on Liverand Digestive Diseases (CIBEREHD) and CIBER on Physiopathology of Obesity and Nutrition (CIBEROBN) are an initiative from Carlos III National Institute of Health, Spain.
dc.description.sponsorshipWe are grateful to Aase Handberg for her highly useful and constructive comments. Also, the authors thank Nuria Villalmanzo (she holds a fellowship from Pla Estratègic i Innovació en Salut PERIS, Departament de Salut de la Generalitat de Catalunya), and Jordi Real for their valuable assistance in conducting the laboratory technics and statistical analysis, respectively. We thank the IGTP Flow Citometry Core Facility and staff (Marco Fernández and Gerard Requena) for technical assistance in flow cytometry experiments and analysis. We want to particularly acknowledge the patients, IGTP-HUGTP, and IRBLleida (B.0000682) Biobanks integrated in the Spanish National Biobanks Network of Instituto de Salud Carlos III (PT17/0015/0045 and PT17/0015/0027 respectively,) and Tumor Bank Network of Catalonia for its collaboration.
dc.language.isoengca_ES
dc.publisherMDPIca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.3390/jcm8050710ca_ES
dc.relation.ispartofJournal of Clinical Medicine, 2019, vol. 8, num. 5ca_ES
dc.rightscc-by (c) Castelblanco et al., 2019ca_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectsCD36ca_ES
dc.subjectType 1 diabetes mellitusca_ES
dc.subjectType 2 diabetes mellitusca_ES
dc.titleCirculating Soluble CD36 is Similar in Type 1 and Type 2 Diabetes Mellitus versus Non-Diabetic Subjectsca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.3390/jcm8050710


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

cc-by (c) Castelblanco et al., 2019
Except where otherwise noted, this item's license is described as cc-by (c) Castelblanco et al., 2019